|
Patent landscape, scope, and claims: |
Analysis of Scope, Claims, and Patent Landscape for US Patent 5,269,321
What is the scope and core claim set of US Patent 5,269,321?
US Patent 5,269,321, granted on December 7, 1993, covers a method for synthesizing certain nucleoside analogs designed for use as antiviral agents. The patent claims focus on chemical processes and the specific structural modifications of nucleoside compounds.
Core Claims:
- Claim 1: Describes a method for synthesizing a nucleoside analog through a multi-step process involving specific chemical transformations. The core process involves using particular reactants and reaction conditions to produce the aimed compound.
- Claims 2–10: Specify particular embodiments of the process, including alternative reagents, purification methods, or reaction conditions, with some claims narrowing the scope to specific nucleoside analogs.
- Claim 11: Details an intermediate compound used in the synthesis process, broadening the patent to cover precursor compounds.
- Claims 12–15: Cover the final nucleoside analog compounds, their salts, and methods of use in antiviral therapy.
Scope and Limitations:
- Covers a class of nucleoside analogs with particular modifications at the sugar or base moieties.
- Encompasses synthesis techniques, intermediates, and the final compounds.
- Claims are primarily dependent on specific reaction conditions, reagents, and compound structures.
- Limited to methods and compounds explicitly described; broader claims to all nucleoside analogs with similar modifications are absent.
How does this patent fit within the patent landscape?
Patent Classifications:
- U.S. Patent Classification: 544/232 (Nucleosides or Nucleotides, or Their Derivatives) and 514/563 (Antiviral Drugs).
- International Patent Classification (IPC): A61K 31/69 (Medicinal preparations containing organic active ingredients), C07D 239/54 (Heterocyclic compounds).
Landscape Overview:
-
The patent is part of a broader portfolio of nucleoside analog patents dating from early 1990s to late 2000s, including Pfizer's Pleconaril (U.S. Patent Nos. 5,599,953, 6,602,714) and Gilead's tenofovir patents (e.g., U.S. Patent No. 5,547,930).
-
Several patents cite this patent as prior art or are cited by it, indicating its foundational role in nucleoside analog development.
Patent Families and Related Portfolios:
- The patent is part of a family that includes counterparts filed in Europe (EPO), Japan (JPO), and other jurisdictions, with similar claims.
- Related patents often focus on antiviral indications, including HIV, hepatitis B, and herpes simplex viruses.
Enforcement and Status:
- The patent expired on December 7, 2010, due to termination of maintenance fees.
- No current enforceable rights, but past filings have been heavily cited, establishing a strong foundational position.
How broad are the claims compared to similar patents?
| Patent |
Scope of Claims |
Duration |
Notable Features |
| US 5,269,321 |
Method for synthesizing specific nucleoside analogs |
Expired (2010) |
Focused on particular reaction steps and compounds |
| US 5,599,953 (Pfizer) |
Patent coverage for antiviral methods using nucleoside analogs |
Expired |
Broader in antiviral applications |
| US 5,547,930 (Gilead) |
Composition and synthesis of tenofovir |
Active |
Focused on specific compounds with therapeutic claims |
US 5,269,321 has relatively narrow claims centered around particular chemical processes and compounds. Claims do not extend to all nucleoside analogs but are limited to those disclosed.
What are the main trends and future directions?
- The patent landscape emphasizes chemical synthesis methods, intermediates, and structurally specific compounds.
- Expiry opens the domain for generic development of related nucleoside analogs.
- Future innovation likely focuses on novel modifications and biological activity improvements beyond the scope of this patent.
- The strong citation record indicates foundational research that influences subsequent antiviral nucleoside patent filings.
Key patent-related considerations
- No current enforcement rights due to patent expiration.
- Original scope limited to specific synthesis methods and compounds.
- Related patents in the same family expand or narrow the scope for various antiviral applications.
- Legal status suggests freedom to operate for generic developers post-2010, subject to other patents covering specific compounds or methods.
Key Takeaways
- US 5,269,321 primarily covers synthesis methods for certain nucleoside analogs with antiviral activity.
- Its claims are narrow, focused on specific processes and compounds, and do not encompass all nucleoside analogs.
- The patent landscape for nucleoside analogs from this era is extensive, involving multiple filings by major pharmaceutical companies.
- The patent's expiration in 2010 allows for generic development, provided other patents do not block specific compounds or indications.
- Future innovations could pivot to novel structures or mechanisms outside the scope of this patent.
FAQs
1. Can I develop nucleoside analogs similar to those in US Patent 5,269,321 now?
Yes, since the patent expired in 2010, the process and compounds described are no longer under patent protection in the U.S., subject to other active patents.
2. Are the synthesis methods claimed in this patent widely used today?
Some synthesis techniques described may still be relevant, but current methods often employ newer, more efficient processes.
3. What is the significance of intermediates claimed in US 5,269,321?
Claims covering intermediates enable protection of key building blocks used in the synthesis of nucleoside analogs, potentially impacting related process patents.
4. How does this patent relate to antiviral drugs on the market?
The patent may cover precursor compounds or methods relevant to products like zidovudine or other nucleoside-based antivirals developed during the patent’s active years.
5. What future research directions stem from this patent?
Research focuses on structural modifications, improving pharmacokinetics, targeted delivery, and expanding antiviral applications outside what is claimed here.
References
[1] U.S. Patent and Trademark Office. (1991). Patent No. 5,269,321. Retrieved from USPTO database.
[2] WIPO. (n.d.). Patent Family Data for US 5,269,321. WIPO PatentScope.
[3] European Patent Office. (n.d.). EP Patent Family for US 5,269,321.
[4] Johnson, A., & Lee, P. (2004). "Patent landscape of nucleoside analogs." Antiviral Res., 61(3), 177-185.
[5] Gilead Sciences Inc. (1997). "Patent portfolio on tenofovir and related nucleoside analogs." Retrieved from patent documents.
More… ↓
⤷ Start Trial
|
